NR4A1 and breast cancer: The approval of Cyclin Dependent Kinase 4 and 6 (CDK 4/6) inhibitors changed the treatment landscape for patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer.